No clinical evidence for performing trough plasma and
intracellular imatinib concentrations monitoring in patients
with chronic myelogenous leukaemia

J 2014

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

RÁČIL, Zdeněk, Filip RÁZGA, Hana KLAMOVA, Jaroslava VOGLOVÁ, Petra BELOHLAVKOVA et. al.

Základní údaje

Originální název

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

Autoři

RÁČIL, Zdeněk (203 Česká republika, garant, domácí), Filip RÁZGA (703 Slovensko), Hana KLAMOVA (203 Česká republika), Jaroslava VOGLOVÁ (203 Česká republika), Petra BELOHLAVKOVA (203 Česká republika), Ludmila MALÁSKOVÁ (203 Česká republika), David POTĚŠIL (203 Česká republika, domácí), Jan MUŽÍK (203 Česká republika, domácí), Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Katerina Machova POLAKOVA (203 Česká republika), Zbyněk ZDRÁHAL (203 Česká republika, domácí), Jana MALAKOVA (203 Česká republika), Jiri SUTTNAR (203 Česká republika), Jan DYR (203 Česká republika) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Hematological Oncology, Hoboken, WILEY-BLACKWELL, 2014, 0278-0232

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Full Text

Impakt faktor

Impact factor: 3.084

Kód RIV

RIV/00216224:14740/14:00074752

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1002/hon.2091

UT WoS

000340570100005

Klíčová slova anglicky

CML; imatinib; plasma concentration; cell-asscociated concentration

Štítky

EL OK, kontrola MP, ok, podil, rivok, SCOPUS

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 12. 2019 10:25, Mgr. Marie Šípková, DiS.

Anotace

V originále

This multicentre study focused on monitoring imatinib mesylate(IMA)trough plasma(Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations. All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or bodymass index) impact onmeasured IMA Ctrough. The IMA Ctrough decreased during the first 6months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p=0.273) and the 12th month (p = 0.193) of therapy. Our data obtained from real life clinical practice did not find a benefit of routine and regular IMA Ctrough nor IMA Cintrac therapeutic drug monitoring in CML patients or for subsequent adjustments of the IMA dose based on these results. Moreover, actual alpha 1-acid glycoprotein plasma concentration should be used for proper interpretation of IMA Ctrough results.

Návaznosti

CZ.1.05/1.1.00/02.0068, interní kód MU

Název: CEITEC - středoevropský technologický institut (Akronym: CEITEC)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC - středoevropský technologický institut, 1.1 Evropská centra excelence

Přiložené soubory

EL_1122749_No_clinical_evidence.pdf

Požádat o autorskou verzi souboru

Citovat

RÁČIL, Zdeněk, Filip RÁZGA, Hana KLAMOVA, Jaroslava VOGLOVÁ, Petra BELOHLAVKOVA, Ludmila MALÁSKOVÁ, David POTĚŠIL, Jan MUŽÍK, Daniela ŽÁČKOVÁ, Katerina Machova POLAKOVA, Zbyněk ZDRÁHAL, Jana MALAKOVA, Jiri SUTTNAR, Jan DYR a Jiří MAYER. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. Hematological Oncology. Hoboken: WILEY-BLACKWELL, 2014, roč. 32, č. 2, s. 87-93. ISSN 0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2091.

@article{1122749,
   author = {Ráčil, Zdeněk and Rázga, Filip and Klamova, Hana and Voglová, Jaroslava and Belohlavkova, Petra and Malásková, Ludmila and Potěšil, David and Mužík, Jan and Žáčková, Daniela and Polakova, Katerina Machova and Zdráhal, Zbyněk and Malakova, Jana and Suttnar, Jiri and Dyr, Jan and Mayer, Jiří},
   article_location = {Hoboken},
   article_number = {2},
   doi = {http://dx.doi.org/10.1002/hon.2091},
   keywords = {CML; imatinib; plasma concentration; cell-asscociated concentration},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia},
   url = {http://onlinelibrary.wiley.com/doi/10.1002/hon.2091/abstract},
   volume = {32},
   year = {2014}
}

TY  - JOUR
ID  - 1122749
AU  - Ráčil, Zdeněk - Rázga, Filip - Klamova, Hana - Voglová, Jaroslava - Belohlavkova, Petra - Malásková, Ludmila - Potěšil, David - Mužík, Jan - Žáčková, Daniela - Polakova, Katerina Machova - Zdráhal, Zbyněk - Malakova, Jana - Suttnar, Jiri - Dyr, Jan - Mayer, Jiří
PY  - 2014
TI  - No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia
JF  - Hematological Oncology
VL  - 32
IS  - 2
SP  - 87-93
EP  - 87-93
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - CML
KW  - imatinib
KW  - plasma concentration
KW  - cell-asscociated concentration
UR  - http://onlinelibrary.wiley.com/doi/10.1002/hon.2091/abstract
L2  - http://onlinelibrary.wiley.com/doi/10.1002/hon.2091/abstract
N2  - This multicentre study focused on monitoring imatinib mesylate(IMA)trough plasma(Ctrough) and intracellular (IMA Cintrac) concentrations in 228 chronic myelogenous leukaemia patients. We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations. All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or bodymass index) impact onmeasured IMA Ctrough. The IMA Ctrough decreased during the first 6months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p=0.273) and the 12th month (p = 0.193) of therapy. Our data obtained from real life clinical practice did not find a benefit of routine and regular IMA Ctrough nor IMA Cintrac therapeutic drug monitoring in CML patients or for subsequent adjustments of the IMA dose based on these results. Moreover, actual alpha 1-acid glycoprotein plasma concentration should be used for proper interpretation of IMA Ctrough results.
ER  -

RÁČIL, Zdeněk, Filip RÁZGA, Hana KLAMOVA, Jaroslava VOGLOVÁ, Petra BELOHLAVKOVA, Ludmila MALÁSKOVÁ, David POTĚŠIL, Jan MUŽÍK, Daniela ŽÁČKOVÁ, Katerina Machova POLAKOVA, Zbyněk ZDRÁHAL, Jana MALAKOVA, Jiri SUTTNAR, Jan DYR a Jiří MAYER. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. \textit{Hematological Oncology}. Hoboken: WILEY-BLACKWELL, 2014, roč.~32, č.~2, s.~87-93. ISSN~0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2091.

Podrobný výpis o publikaci